Lorena Fariñas-Madrid

751 total citations
24 papers, 280 citations indexed

About

Lorena Fariñas-Madrid is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Lorena Fariñas-Madrid has authored 24 papers receiving a total of 280 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Reproductive Medicine and 7 papers in Obstetrics and Gynecology. Recurrent topics in Lorena Fariñas-Madrid's work include Ovarian cancer diagnosis and treatment (9 papers), Endometrial and Cervical Cancer Treatments (7 papers) and PARP inhibition in cancer therapy (7 papers). Lorena Fariñas-Madrid is often cited by papers focused on Ovarian cancer diagnosis and treatment (9 papers), Endometrial and Cervical Cancer Treatments (7 papers) and PARP inhibition in cancer therapy (7 papers). Lorena Fariñas-Madrid collaborates with scholars based in Spain, United States and United Kingdom. Lorena Fariñas-Madrid's co-authors include Ana Oaknin, Juan Francisco Grau-Béjar, Qian Tan, Yeh Chen Lee, Jeffrey P. Bruce, Valerie Bowering, Iulia Cirlan, Marsela Braunstein, Neesha C. Dhani and Ainhoa Madariaga and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Lorena Fariñas-Madrid

24 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lorena Fariñas-Madrid Spain	8	205	102	91	61	40	24	280
Elena Giudice Italy	8	134 0.7×	74 0.7×	93 1.0×	50 0.8×	29 0.7×	33	240
Floriana Camarda Italy	7	136 0.7×	48 0.5×	89 1.0×	40 0.7×	18 0.5×	27	236
Ilaria Cuccu Italy	9	92 0.4×	125 1.2×	51 0.6×	132 2.2×	23 0.6×	20	283
Kassondra Meyer United States	9	269 1.3×	128 1.3×	123 1.4×	18 0.3×	96 2.4×	14	355
Beata Maćkowiak-Matejczyk Poland	8	96 0.5×	125 1.2×	57 0.6×	66 1.1×	39 1.0×	14	243
Imre Pete Hungary	10	78 0.4×	89 0.9×	110 1.2×	55 0.9×	14 0.3×	22	261
Angelika Kaufmann United Kingdom	8	93 0.5×	77 0.8×	92 1.0×	51 0.8×	11 0.3×	14	207
Marthe M. de Jonge Netherlands	8	133 0.6×	171 1.7×	111 1.2×	110 1.8×	10 0.3×	8	307
Heather Derocher Canada	6	288 1.4×	50 0.5×	65 0.7×	79 1.3×	196 4.9×	6	406
Gonzalo Giornelli Argentina	5	110 0.5×	241 2.4×	84 0.9×	254 4.2×	25 0.6×	8	421

Countries citing papers authored by Lorena Fariñas-Madrid

Since Specialization

Citations

This map shows the geographic impact of Lorena Fariñas-Madrid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorena Fariñas-Madrid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorena Fariñas-Madrid more than expected).

Fields of papers citing papers by Lorena Fariñas-Madrid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorena Fariñas-Madrid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorena Fariñas-Madrid. The network helps show where Lorena Fariñas-Madrid may publish in the future.

Co-authorship network of co-authors of Lorena Fariñas-Madrid

This figure shows the co-authorship network connecting the top 25 collaborators of Lorena Fariñas-Madrid. A scholar is included among the top collaborators of Lorena Fariñas-Madrid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorena Fariñas-Madrid. Lorena Fariñas-Madrid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhatia, Shailender, Suzanne L. Topalian, William H. Sharfman, et al.. (2025). Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. Journal of Clinical Oncology. 43(9). 1137–1147. 7 indexed citations

Fidalgo, José Alejandro Pérez, Ignace Vergote, Erika Hamilton, et al.. (2024). PO003/#1168 Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53WT advanced or recurrent endometrial cancer: follow up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. A16–A17. 1 indexed citations

Colombo, Nicoletta, Kenichi Harano, Francesca Galli, et al.. (2024). 546 AtTEnd/ENGOT-EN7: phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma. A21.1–A21. 2 indexed citations

Grau-Béjar, Juan Francisco, et al.. (2023). Advances in immunotherapy in cervical cancer. International Journal of Gynecological Cancer. 33(3). 403–413. 18 indexed citations

Oaknin, Ana, Lorena Fariñas-Madrid, Lainie P. Martin, et al.. (2023). Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.. Journal of Clinical Oncology. 41(16_suppl). 5508–5508. 21 indexed citations

Bhatia, Shailender, Suzanne L. Topalian, William H. Sharfman, et al.. (2023). Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358).. Journal of Clinical Oncology. 41(16_suppl). 9506–9506. 11 indexed citations

Poveda, Andrés, Raquel López-Reig, Ana Oaknin, et al.. (2022). Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers. 14(4). 915–915. 5 indexed citations

Fariñas-Madrid, Lorena, María Jesús Rubio, Andrés Redondo, et al.. (2021). 798P A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001. Annals of Oncology. 32. S761–S762. 3 indexed citations

Poveda, Andrés, Ana Oaknin, Ignacio Romero, et al.. (2021). A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Scientific Reports. 11(1). 4433–4433. 12 indexed citations

10.

Fariñas-Madrid, Lorena, Marı́a Santacana, Andrés Redondo, et al.. (2021). 731 Biomarker analysis of the phase 2 study of pembrolizumab in combination with doxorubicin in advanced endometrial cancer: TOPIC trial/VHIO10001. A118.2–A119. 2 indexed citations

11.

Lheureux, Stéphanie, Ana Oaknin, Swati Garg, et al.. (2020). EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Clinical Cancer Research. 26(16). 4206–4215. 95 indexed citations

12.

Stradella, Agostina, Melissa L. Johnson, Sanjay Goel, et al.. (2020). 530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ). Annals of Oncology. 31. S465–S466. 1 indexed citations

13.

Léary, Alexandra, Purificación Estévez-García, Renaud Sabatier, et al.. (2020). 864P Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer. Annals of Oncology. 31. S639–S640. 1 indexed citations

14.

Rodríguez-Freixinós, Víctor, Lorena Fariñas-Madrid, Ana C. Garrido-Castro, et al.. (2019). Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open. 4(2). e000444–e000444. 11 indexed citations

15.

Grau-Béjar, Juan Francisco, Lorena Fariñas-Madrid, & Ana Oaknin. (2019). A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). International Journal of Gynecological Cancer. 30(1). 139–143. 61 indexed citations

16.

Rodríguez-Freixinós, Víctor, Lorena Fariñas-Madrid, Marta Gil-Martín, et al.. (2018). Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Gynecologic Oncology. 152(2). 270–277. 9 indexed citations

17.

Poveda, Andrés, Ana Oaknin, Ignacio Romero, et al.. (2017). Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 5573–5573. 2 indexed citations

18.

Oaknin, Ana, I. Vergote, Isabelle Ray‐Coquard, et al.. (2017). Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179. Annals of Oncology. 28. v335–v335. 6 indexed citations

19.

Fariñas-Madrid, Lorena, Guillermo Villacampa, Paolo Nucíforo, et al.. (2017). Impact of genomic heterogeneity on PI3K/AKT/mTOR inhibitors (PAMi) efficacy in gynecologic cancer (GYN) patients (pts).. Journal of Clinical Oncology. 35(15_suppl). 5569–5569. 1 indexed citations

20.

Sanz‐García, Enrique, Marta Gil-Martín, Lorena Fariñas-Madrid, et al.. (2014). Impact of Demographic Characteristics, Staging Methods and Treatment in a European Locally Advanced Cervical Cancer (Lacc) Population. Annals of Oncology. 25. iv320–iv320. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact